Keytruda Qlex
Keytruda Qlex ingredients
| Active ingredient | Strength |
|---|---|
| Pembrolizumab | 165 mg/mL |
| Berahyaluronidase Alfa | 2000 U/mL |
What Keytruda Qlex is used for
The FDA lists the approved uses on the official label (below). In the EU, pembrolizumab is approved as Keytruda for:
Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC) Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non small cell lung carcinoma at high risk of recurrence in adults Keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Keytruda Qlex
- Generic name
- Pembrolizumab and berahyaluronidase alfa-pmph
- Made by
- Merck Sharp & Dohme LLC
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Endoglycosidase, Programmed Death Receptor-1 Blocking Antibody
- FDA approval
- Biologic licence (BLA) BLA761467
- On the US market since
- 2025
Official information
- MedlinePlus drug information (search for Pembrolizumab and berahyaluronidase alfa-pmph)
In India
- Pembrolizumab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Keytruda Qlex?
Keytruda Qlex (Pembrolizumab and berahyaluronidase alfa-pmph) is a cancer medicine made by Merck Sharp & Dohme LLC, approved by the US FDA.
What are the ingredients of Keytruda Qlex?
Keytruda Qlex contains Pembrolizumab (165 mg/mL); Berahyaluronidase Alfa (2000 U/mL).
Is Keytruda Qlex approved in Europe?
The same active substance is approved in the EU as Keytruda.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA